Listen to this article · 5 min listen

For digital care companies, going public has completely changed the evidence game. What used to be a good-enough marketing asset, a nice case study or an internal ROI deck, is now a hard requirement, picked apart by institutional investors and corporate development teams. That outcomes record isn’t a persuasive tool anymore. It’s a primary driver of your company’s valuation.

The Listing Event as an Evidence Standard Setter

Hinge Health’s NYSE listing in May 2025 was the moment this new era became undeniable. After securing $854M in pre-IPO funding, Hinge Health reported Q1 2025 revenue of $123.8M, a 50% year-over-year jump. But they went public on the back of a specific, recorded benchmark: the Hinge Health Peer-Reviewed ROI Study. That study showed an average cost savings of $2,941 per member per year, a figure that became the backbone of their public market story. The IPO turned that number from a marketing claim into a foundational component of the company’s S-1 filing, allowing investors to bake it directly into their valuation models and assess its financial viability Hinge Health S-1 filing.

How Buyers Evaluate Cost Evidence: The CFO’s Lens

Institutional investors and corporate dev teams now evaluate digital health solutions just like the most sophisticated buyers (employers and payers) do. Jane Sarasohn-Kahn has been tracking this for years, and she lays out a framework that’s basically a CFO’s playbook. It starts with digging into claims data and then moves to a tough assessment of the published record, prioritizing independent verification over what the vendor’s marketing department says. This is how you prove that your claimed cost savings are rooted in actual financial outcomes, not just spreadsheet projections Jane Sarasohn-Kahn on digital health ROI evaluation.

A huge piece of this, especially for digital health tools focused on prevention, is understanding the reimbursement field. Take the CMS MSSP (Medicare Shared Savings Program) pathway. Why does it matter so much? It’s a recorded, government-backed structure that directly translates prevention results into actual payments. For a CFO looking at a digital health investment, seeing that a company can plug into a shared savings model provides a clear line of sight to realizing financial benefits from reduced hospital visits or better health outcomes, confirming the whole economic model is sustainable and scalable.

The Peer Set and Consistent Market Signals

It’s not just Hinge Health. The rest of the market is getting the same memo. Sword Health, which hit a $4B valuation in June 2025, and Omada Health have built their growth on their own published outcomes. Sword Health, for instance, has a documented claims reduction of $3,177 per member for MSK conditions, while Hinge Health’s is $2,941 for the same. In cardiac care, Hello Heart stands as a benchmark, showing per-member savings of $1,700 and a 47% reduction in inpatient admissions. These companies get it. Strong, independently validated ROI is the price of admission for sustained growth and investor confidence. The market signal is clear: evidence is a listing requirement, full stop.

While you can’t do a perfect apples-to-apples comparison of ROI across different conditions (the cost structures are just too different), the numbers still provide some directional insight. For example, Hello Heart’s cardiac savings are cited between $1,434 (per Aon) and $1,709 (per Value in Health) per member per year. You can benchmark that against Hinge Health’s MSK savings of $2,941 per member per year and Sword Health’s MSK savings of $3,177 per member. Even though they’re for different health issues, these figures all point to the same truth: digital health platforms have to demonstrate a clear, quantifiable financial return to be taken seriously PMPY savings benchmarks across digital health platforms.

What the Listing Standard Now Requires

Going public, or even just taking a significant late-stage private funding round, puts a company’s evidence under a powerful microscope. The standard for evidence is now peer-reviewed studies, transparent methodologies, and verifiable claims data, not internal reports or a few happy customer anecdotes. This requirement includes proving financial ROI for the employers and payers footing the bill, not just showing clinical efficacy. Investors are looking for companies that have built a fortress of outcomes data, demonstrating consistent, measurable cost savings alongside clinical improvements. The ability to prove a strong ROI with rigorous research is now fundamental to a digital care company’s valuation and its appeal to institutional capital. In this maturing market, only solutions with a proven economic impact are going to thrive.

Frequently Asked Questions

What is the primary driver of valuation for digital care companies in the public market?

The primary driver of valuation is the company’s clinical outcomes record. This evidence has transitioned from a marketing asset to a core valuation driver and a non-negotiable requirement for institutional investors and corporate development teams.

What kind of evidence is now required by institutional investors and corporate development teams for digital care companies?

They require robust, independently verified, and peer-reviewed evidence, often starting with claims data. This moves beyond internal ROI projections or marketing case studies to verifiable financial outcomes.

How do sophisticated buyers, like employers and payers, evaluate digital health solutions, and how does this align with investor expectations?

Sophisticated buyers evaluate solutions through a CFO’s lens, examining claims data and published records, prioritizing independent verification. This aligns with investor expectations for verifiable cost savings rooted in financial outcomes, not just projected benefits.

Can you provide examples of how specific digital care companies have demonstrated their ROI to investors?

Hinge Health, Sword Health, and Hello Heart have all emphasized published outcomes. Hinge Health documented $2,941 per member per year in cost savings, Sword Health showed a $3,177 per member claims reduction, and Hello Heart demonstrated $1,700 per member savings in cardiac care.